金币
UID176556
帖子
主题
积分25051
注册时间2014-6-6
最后登录1970-1-1
听众
性别保密
|
欢迎您注册蒲公英
您需要 登录 才可以下载或查看,没有帐号?立即注册
x
Figure 3 is a simple but effective example of how this can be implemented in practice. There is nothing fundamentally new here, except for the fact that the Guidance introduces some alternative terminology, and that the proposed framework is depicted pictorially.The approach can be summarized as follows:
• The purpose of a unit operation is to deliver or protect some aspect(s) of the target product profile (also known as attributes at risk).
• The identification and management of significant variables constitutes the control strategy for the unit operation.
• Significant variables can entail equipment monitoring (EM), material analysis (MA), or quality control (QC) testing.
• Process analytical technology (PAT) is treated as a means to an end, rather than a variable per se, within the framework. PAT does not replace required in-process testing and finished product release testing, although it can provide realtime data for use in such cGMP tests.(这句话如何理解呢??哪位大神指教一下,非常感谢)
• The compilation of control strategy commitments can be prospective or retrospective (new versus legacy products), and be based on a combination of manufacturing experience, technical literature, quality by design, risk analysis, etc.
选自<FDA 2011 Process Validation Guidance: Process Validation Revisited>
http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-afda-orgs/documents/document/ucm334560.pdf
|
|